New Autonomous ITVS to Boost Operational Efficiency at Jebel Ali Port in Deal Between DP World, UAE Region and DGWORLD
Leading trade enabler, DP World, UAE Region and the autonomous vehicle, robotics and AI specialist DGWorld has entered a contractual agreement to equip Jebel Ali Port with a fleet of Autonomous Internal Terminal Vehicles (AITVs), including all related integrations in the existing operation processes and infrastructures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005515/en/
Mohammed Al Muallem, CEO and Managing Director, DP World, UAE Region (Photo: AETOSWire)
DP World, UAE Region once again manifests its leadership and visionary role by introducing autonomous vehicles and related technologies into their daily operations, which supports their initiatives and strategy of introducing digitalization and newest technologies as the new global standard for traditional port operations, supply chains and to enable the future of trade.
The contract signed between the two sides states, DGWorld will deliver and integrate their autonomous technology at the existing ITV fleet in multiple phases, with the goal to further increase the overall efficiency of the terminal and reduce the overall size of the currently used fleet, at the same time.
Mohammed Al Muallem, CEO and Managing Director, DP World, UAE Region, said: "At DP World, UAE Region, we employ today's frontline technologies such as robotics, automation, Internet of Things, Big Data, virtual reality and cybersecurity to build and sustain our efficiencies. As a trade enabler, technology has powered and underpinned our capabilities as an essential economic service at a time when the UAE needs us most. Digital technology will continue to drive smart trade for DP World, UAE Region and help us create a better future for all."
Bilal Al-Zoubi – DGWorld Founder & CEO, added: “We are so proud of the Trust received by DP World, one of the leading global Port Operators and smart trade enablers, to work under their umbrella to deliver these advanced AI, Robotics & Autonomous Technologies. Following the visionary leadership of DP World and Dubai to be one most advanced & smartest Ports as well as City in the world, we are investing heavily in the best Minds, Practices and Resources to develop those Applications & Technologies to match their operational requirements based on the Highest International Standards and now we are moving stronger to expand our current operations locally and globally with the great support of DP World and the Dubai - UAE Government.”
Previous trials of this new technology have shown that it is capable of unlocking new potentials for efficient and economical automation of already existing Container Terminals in combination with the intensive utilization of new AI-based software solutions, which have been integrated by the teams of both parties, jointly.
For more information please visit: www.dgworld.com
View source version on dgworld.com: https://www.dgworld.com/Press-Details/NEW-AUTONOMOUS-ITVs-TO-BOOST-OPERATIONAL-EFFICIENCY-AT-JEBEL-ALI-PORT-IN-DEAL-BETWEEN-DP-WORLD--UAE-REGION-AND-DGWORLD/26
Find us on LinkedIn: https://www.linkedin.com/in/dgworld/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005515/en/
Contact information
DGWorld Media Team
Eng. Yasmin Enazi
Projects Director
M: +971 50 6600513
Email: yasmin@dgworld.com
Mr. Gautam Ahuja
Commercial Director
M: +971 50 6600512
Email: gautam@dgworld.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release
CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom